newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

  • Aligos Therapeutics reported second quarter 2026 financial results & recent business progress on August 06, 2026.
  • The company secured a $25 million upfront payment from partner Amoytop for an exclusive Greater China license for pevifoscorvir sodium.
  • Aligos received a $3 million milestone payment from Amoytop following the IND approval of the ASO candidate ALG-170675 in China.
  • Pevifoscorvir sodium received Breakthrough Therapy Designation from China's NMPA & completed enrollment for the Phase 2 B-SUPREME study.
  • Topline data for the B-SUPREME study is expected in late Q3 2027 for both HBeAg+ & HBeAg- cohorts.
  • ALG-170675, a next-generation ASO, has shown improved activity over bepirovirsen & is advancing to Phase 1 SAD/MAD studies in China funded by Amoytop.
  • Aligos retains ex-Greater China rights for ALG-170675 & may conduct a Phase 2 study in 2028 potentially including combination therapy.
  • Cash, cash equivalents, & investments totaled $30.4 million as of June 30, 2026, excluding the July 2026 $25 million upfront payment.
  • Net loss for the three months ended June 30, 2026, was $1.5 million, a decrease from $15.9 million in the same period of 2025.
  • Research & development expenses increased to $24.1 million due to third-party costs for the pevifoscorvir sodium Phase 2 trial.
  • General & administrative expenses remained flat at $5.6 million for the quarter.
  • Interest & other income was $0.2 million, while the change in fair value of 2023 common warrants generated $3.0 million in income.
  • Aligos expects its current cash resources to fund operations through the fourth quarter of 2026.